Cancer Family
Squamous Cell Neoplasm
CI-CAN-00000359Explore in graph →
Non-malignant1,024 active trials9 approved drugs78 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000359Explore in graph →
Clinical trials
3,210 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03194906 | Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors | completed | Phase 2 | 41 | St. Jude Children's Research HospitalOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT05721443 | Cetuximab Plus Dalpicilib in Patients With HPV Negative, PD-1 Resistant R/M HNSCC | completed | Phase 2 | 28 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 |
| Jun 18, 2026 |
| clinicaltrials |
| NCT04635423 | Efficacy, Immunogenicity, and Safety Study of V503 (9-valent Human Papillomavirus [9vHPV] Vaccine) in Japanese Males (V503-064) | completed | Phase 3 | 1,059 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Jun 11, 2026 | clinicaltrials |
| NCT04603248 | A Study for Identification of Immune Determinants for Response to Nivolumab in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma | completed | N/A | 50 | Yonsei UniversityOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT03838601 | Role of Microbiome as a Biomarkers in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2(ROMA LA-OPSCC2) | completed | N/A | 30 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04733495 | Group-Mediated Cognitive Behavioral Resistance Exercise Intervention in Head and Neck Cancer Patients Undergoing Chemoradiation Treatment | completed | N/A | 20 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04881045 | Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors. | completed | Phase 1 | 29 | PfizerINDUSTRY | 2 | Jun 2, 2026 | clinicaltrials |
| NCT04847466 | Immunotherapy Combination: Irradiated PD-L1 CAR-NK Cells Plus Pembrolizumab Plus N-803 for Subjects With Recurrent/Metastatic Gastric or Head and Neck Cancer | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05294900 | Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients(NEOS) | completed | Phase 2 | 79 | Yonsei UniversityOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02254278 | Reduced-Dose Intensity-Modulated Radiation Therapy With or Without Cisplatin in Treating Patients With Advanced Oropharyngeal Cancer | completed | Phase 2 | 316 | NRG OncologyOTHER | 4 | May 22, 2026 | clinicaltrials |
| NCT02860923 | Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy(CRANIOEXE) | completed | Phase 3 | 42 | University Hospital, BordeauxOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03336606 | Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03789097 | Vaccination With Flt3L, Radiation, and Poly-ICLC | completed | Phase 1 / Phase 2 | 17 | Icahn School of Medicine at Mount SinaiOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03494322 | EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck Cancer(EACH) | completed | Phase 2 | 16 | University College, LondonOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05278039 | Training Swallowing Initiation During Expiration | completed | N/A | 88 | Northwestern UniversityOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT02841748 | A Randomized, Double-Blind Phase II Study of Adjuvant Pembrolizumab Versus Placebo in Head and Neck Cancers at High Risk for Recurrence- the PATHWay Study | completed | Phase 2 | 100 | University of ChicagoOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT04369937 | HPV-16 Vaccination and Pembrolizumab Plus Cisplatin for "Intermediate Risk" HPV-16-associated Head and Neck Squamous Cell Carcinoma | completed | Phase 2 | 18 | Dan ZandbergOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT03552718 | QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers. | completed | Phase 1 | 5 | NantBioScience, Inc.INDUSTRY | 1 | May 7, 2026 | clinicaltrials |
| NCT04665843 | A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck(SKYSCRAPER-09) | completed | Phase 2 | 123 | Hoffmann-La RocheINDUSTRY | 13 | May 5, 2026 | clinicaltrials |
| NCT06094829 | Tobacco and Alcohol Influence on Oncogenic Drivers and Somatic Evolution in the Oral Mucosa(DEMO) | completed | — | 100 | Hospices Civils de LyonOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT05865990 | HER3-DXd in Breast Cancer and NSCLC Brain Metastases and Solid Tumor Leptomeningeal Disease(TUXEDO-3) | completed | Phase 2 | 63 | MedSIROTHER | 2 | May 4, 2026 | clinicaltrials |
| NCT05120947 | Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers(HART-HN) | completed | N/A | 18 | Medical College of WisconsinOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02664935 | National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer | completed | Phase 2 | 423 | University of BirminghamOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06971276 | Assessing the Utility of Plasma ctHPVDNA for Anal Cancer Screening(SCAN-LITE) | completed | — | 104 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05213884 | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC | completed | Phase 2 | 39 | Chongqing University Cancer HospitalOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT03621696 | Surgery Followed by Risk-Directed Post-Operative Adjuvant Therapy for HPV-Related Oropharynx Squamous Cell Carcinoma: "The Minimalist Trial (MINT)"(MINT) | completed | Phase 2 | 63 | Washington University School of MedicineOTHER | 1 | Apr 21, 2026 | clinicaltrials |
| NCT02437851 | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection | completed | Phase 2 | 16 | AIDS Malignancy ConsortiumNETWORK | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03476330 | Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia | completed | Phase 2 | 48 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Apr 20, 2026 | clinicaltrials |
| NCT03574792 | Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy | completed | Phase 2 | 62 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03236935 | Phase Ib of L-NMMA and Pembrolizumab | completed | Phase 1 | 12 | The Methodist Hospital Research InstituteOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT05077709 | IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC | completed | Phase 2 | 63 | IO BiotechINDUSTRY | 3 | Apr 8, 2026 | clinicaltrials |
| NCT02510859 | Nutrition and Life QUality Patients With Head and Neck Cancers(NUQUE2) | completed | N/A | 117 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT02773719 | Biofields Therapy on Warts(MAGNETIK) | completed | N/A | 62 | University Hospital, CaenOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT03370276 | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 95 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT05673577 | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients | completed | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Apr 2, 2026 | clinicaltrials |
| NCT04785820 | A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus | completed | Phase 2 | 190 | Hoffmann-La RocheINDUSTRY | 18 | Mar 27, 2026 | clinicaltrials |
| NCT01783587 | Safety Study of Afatinib and Postoperative Radiation Therapy to Treat Head and Neck Cancer | completed | Phase 1 | 29 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT04480645 | CivaDerm(TM) Surface Therapy Pilot Study | completed | Early Phase 1 | 10 | CivaTech OncologyINDUSTRY | 1 | Mar 24, 2026 | clinicaltrials |
| NCT04188665 | Using MASL to Combat Oral Cancer | completed | Early Phase 1 | 18 | Rowan UniversityOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT01612351 | Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery | completed | Phase 2 | 40 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04042935 | Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC | completed | Phase 1 | 5 | University of Colorado, DenverOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT03313804 | Priming Immunotherapy in Advanced Disease With Radiation | completed | Phase 2 | 76 | John L. Villano, MD, PhDOTHER | 1 | Mar 11, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jun 23, 2026source: clinicaltrials